A Missouri judge has signed off on a settlement of up to $7.25 billion to compensate Roundup users who allege the herbicide caused non-Hodgkin lymphoma. The agreement, approved by St. Louis Circuit Judge Timothy Boyer, covers both current litigants and those diagnosed in the future.

Advertisement

The $7.25 Billion Payout and the $165,000 Ceiling

St. Louis Circuit Judge Timothy Boyer determined that the average individual payouts are fair, noting that the total sum is among the largest in the history of mass tort personal-injury class action settlements. According to the report, the settlement includes $600 million specifically designated for attorney fees.

Individual compensation will vary based on the severity of the illness, the age of the patient at diagnosis, and how the product was used. Agricultural or industrial workers diagnosed with aggressive illness before age 60 could receive an average of $165,000, while those diagnosed at age 78 or older may receive as little as $10,000.

How the June Supreme Court Ruling Shifted Legal Leverage

The timing of this settlement is critical because a June ruling by the U.S. Supreme Court significanly weakened the position of Roundup plaintiffs. the high court ruled that Bayer cannot be sued in state courts over claims that it failed to warn users about cancer, as federal regulations do not require such labels and states are prohibited from adding their own.

This legal shift created a divide among plaintiffs' attorneys. While some argue the settlement amounts are too low, others believe the deal is preferable to the high probability of receiving nothing in light of the Supreme Court's precedent. As the report notes, this ruling effectively closed a primary legal avenue for many claimants.

The 2018 Monsanto Acquisition and the $16 Billion Reserve

Bayer inherited the Roundup legal crisis when it acquired Monsanto in 2018, a move that brought a flood of lawsuits alleging that the active ingredient, glyphosate, causes cancer. To manage these risks, Bayer had previously set aside $16 billion to cover legal costs, though the current $7.25 billion settlement is in addition to those reserves.

The scientific community remains split on the safety of the product. While the World Health Organization's International Agency for Research on Cancer classified glyphosate as probably carcinogenic in 2015, the U.S. Environmental Protection Agency has maintained that it is unlikely to cause cancer when used as directed . In response to the litigation, Bayer has already removed glyphosate from the versions of Roundup sold for residential use.

The 21-Year Payment Window and Gerson Smoger's Warning

The financial structure of the deal is designed for long-term mitigation rather than immediate payout, with Bayer making annual payments into a special fund for up to 21 years. This extended timeline provides Germany-based Bayer with financial certainty and prevents the immediate cash drain that could have led the company to seek bankruptcy protection.

However, attorney Gerson Smoger has criticized the deal as one of the worst future settlements ever conteplated. During a September hearing, Smoger argued that the agreement locks in future claimants for decades and eliminates the possibility of punitive damages, all while allowing the product to remain on the market for agricultural use.

Will the St. Louis Circuit Court Decision Face an Appeal?

Despite Judge Timothy Boyer's approval, the decision remains subject to potentil appeals, leaving a sliver of uncertainty for both Bayer and the claimants.. The legal landscape is currently volatile; for example, while a Georgia jury once awarded plaintiffs $2.1 billion, a Missouri jury sided with Bayer in October in a case involving negligence and fraud.

It remains unclear which specific law firms or claimant groups might attempt to overturn the settlement. Bayer U.S. general counsel Bill Dodero has suggested that recent verdicts signal significant challenges for future Roundup claims,which may discourage further legal challenges to the settlement's terms.